- Home
- OKYO vs CNTX Comparison
OKYO vs CNTX Comparison
Compare OKYO & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- CNTX
- Stock Information
- Founded
- OKYO 2007
- CNTX 2015
- Country
- OKYO United Kingdom
- CNTX United States
- Employees
- OKYO N/A
- CNTX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- CNTX Health Care
- Exchange
- OKYO Nasdaq
- CNTX Nasdaq
- Market Cap
- OKYO 97.8M
- CNTX 102.9M
- IPO Year
- OKYO 2022
- CNTX 2021
- Fundamental
- Price
- OKYO $2.22
- CNTX $1.16
- Analyst Decision
- OKYO Strong Buy
- CNTX Strong Buy
- Analyst Count
- OKYO 1
- CNTX 7
- Target Price
- OKYO $7.00
- CNTX $5.40
- AVG Volume (30 Days)
- OKYO 136.7K
- CNTX 327.7K
- Earning Date
- OKYO 07-18-2025
- CNTX 11-05-2025
- Dividend Yield
- OKYO N/A
- CNTX N/A
- EPS Growth
- OKYO N/A
- CNTX N/A
- EPS
- OKYO N/A
- CNTX N/A
- Revenue
- OKYO N/A
- CNTX N/A
- Revenue This Year
- OKYO N/A
- CNTX N/A
- Revenue Next Year
- OKYO N/A
- CNTX N/A
- P/E Ratio
- OKYO N/A
- CNTX N/A
- Revenue Growth
- OKYO N/A
- CNTX N/A
- 52 Week Low
- OKYO $0.90
- CNTX $0.49
- 52 Week High
- OKYO $3.35
- CNTX $1.97
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- CNTX 50.51
- Support Level
- OKYO $2.33
- CNTX $1.07
- Resistance Level
- OKYO $2.93
- CNTX $1.22
- Average True Range (ATR)
- OKYO 0.22
- CNTX 0.08
- MACD
- OKYO -0.05
- CNTX -0.00
- Stochastic Oscillator
- OKYO 10.46
- CNTX 66.67
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.